A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma

Inclusion Criteria:

- Multiple myeloma meeting the following criteria:

- Pathologically-documented diagnosis of multiple myeloma that is relapsed or is
refractory as defined by the following:

- Relapsed after > or = 2 lines of prior therapy that must include a
proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and, where
approved and available, a CD38-directed cytolytic antibody in any order
during the course of treatment OR refractory to PI, IMiD, and CD38- directed
cytolytic antibody,

- Subjects who could not tolerate a PI, IMiDs, or a CD38-directed cytolytic
antibody are eligible to enroll in the study.

- Measurable disease as per IMWG response criteria

- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2

Exclusion Criteria:

- Extramedullary disease in the absence of any measurable medullary involvement

- Known central nervous system involvement by multiple myeloma

- Autologous stem cell transplantation less than 90 days prior to study day 1

- Multiple myeloma with IgM subtype

- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes)

- Known history of primary plasma cell leukemia or evidence of primary or secondary
plasma cell leukemia at the time of screening

- Waldenstrom's macroglobulinemia

- Amyloidosis

- Treatment with systemic immune modulators including, but not limited to, nontopical
systemic corticosteroids (unless the dose is ≤ 10 mg/day prednisone or equivalent),
cyclosporine, and tacrolimus within 2 weeks before study day 1

- Last anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2
weeks prior to study day 1 or treatment with a therapeutic antibody less than 4 weeks
prior to study day 1 as well as systemic radiation therapy within 28 days prior to
study day 1 or focal radiotherapy within 14 days prior to study day 1.

- Prior treatment with a drug that targets BCMA on tumor cells or any other bi specific
antibody construct or chimeric antigen receptor T cell (CAR-T) infusion for the
treatment of multiple myeloma